Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pregnancy-timing concepts are directionally consistent with the provided label excerpts, but most of the listed statements are not verifiable against the supplied label text (which only includes embryo-fetal toxicity/pregnancy guidance). Multiple dosing-dependency claims (age/weight/pregnancy/other meds/kidney/liver) are unsupported because the dosing section text is not provided.
Category Scores
Accurate Statements
Tivicay is the brand name for dolutegravir.
Not supported by the supplied label excerpts (pregnancy-focused sections only); cannot verify from provided text.
Dolutegravir is used to treat HIV-1 infection as part of combination antiretroviral therapy.
Not supported by the supplied label excerpts (no indication section text provided).
Dolutegravir may be considered during the second and third trimesters of pregnancy if the expected benefit justifies the potential risk to the pregnant woman and the fetus.
Partially aligned with provided label excerpt in 5.3/8.1: later-trimester exposure shows no evidence of increased adverse birth outcomes and dolutegravir may be considered later when benefit justifies risk; the provided excerpts include the specific sentence.
Unsupported Statements
Dolutegravir is an HIV integrase inhibitor.
No label excerpt provided establishing mechanism/class.
Dolutegravir is used in adults and children depending on the approved formulation and dosing.
No indication/pediatric usage text provided.
Dolutegravir dosing depends on age.
No dosing guidance text provided.
Dolutegravir dosing depends on weight (for children).
No dosing guidance text provided.
Dolutegravir dosing depends on pregnancy status.
The pregnancy-related timing guidance is provided, but 'dosing depends on pregnancy status' is broader than the supplied excerpt; dosing details are not provided.
Dolutegravir dosing depends on other HIV medicines taken with it.
Drug interaction/dosing adjustments section text not provided.
Dolutegravir dosing depends on kidney function.
No renal impairment/dosing excerpt provided.
Dolutegravir dosing depends on liver function.
No hepatic impairment/dosing excerpt provided.
Some drug interactions can affect dolutegravir dosing needs.
No interaction section text provided.
Tivicay PD is usually a specific formulation or product variant, but the exact meaning can vary by country, manufacturer, or dispensing system.
No label excerpt provided clarifying the meaning/regional usage of TIVICAY PD.
Common dolutegravir-related side effects can include headache.
Adverse reaction section text not provided.
Common dolutegravir-related side effects can include gastrointestinal symptoms such as nausea.
Adverse reaction section text not provided.
Contradictions
Important Omissions
Pregnancy-testing and initiation guidance details (e.g., perform pregnancy testing before initiation in childbearing potential; 'initiation is not recommended' during active attempts to conceive unless no suitable alternative; contraception counseling).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about dosing dependencies (age/weight/pregnancy status/other HIV meds/kidney/liver) and common side effects are not supported by the supplied label excerpts. While pregnancy-related timing aligns directionally with the provided sections, the absence of specific verified dosing and safety content limits label adherence and could lead to incorrect understanding of appropriate use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims (indication/class, pediatric/adult use, dosing dependencies, drug interaction effects, and adverse reaction frequency) cannot be verified against the provided label text, which only covers pregnancy/embryo-fetal toxicity excerpts.
Suggested Improvement
Limit statements to what is supported by the provided label excerpts (pregnancy/embryo-fetal toxicity timing through first trimester, pregnancy testing/contraception counseling, and later-trimester consideration) and avoid broad dosing/side-effect generalizations unless the relevant sections of the FDA label are included for verification.